Brought to you by 
Cerevel licenses several CNS assets from Pfizer concurrent with spin-off as independent company
29 Oct 2020
Executive Summary
Concurrent with being spun-off from Pfizer Inc. and Bain Capital, Boston-based Cerevel Therapeutics LLC has in-licensed several neuroscience assets from the Big Pharma.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com